DENTSPLY SIRONA Inc (XRAY) receives a strong valuation ranking of 86 from InvestorsObserver data analysis. The proprietary ranking system focuses on the underlying health of a company through analysis of its stock price, earnings, and growth rate. XRAY has a better value than 86% of stocks based on these valuation analytics. Investors primarily focused on buy-and-hold strategies will find the valuation ranking relevant to their goals when making investment decisions.
XRAY gets a 86 Valuation Rank today. Find out what this means to you and get the rest of the rankings on XRAY!
XRAY has a trailing twelve month Price to Earnings (PE) ratio of 25.6 which places it above the histroical average of roughly 15. XRAY is currently trading at a poor value due to investors paying more than what the stock is worth in relation to its earnings. XRAY's trailing-12-month earnings per share (EPS) of 1.90 does not justify its share price in the market. Trailing PE ratios do not factor in the company's projected growth rate, thus, some firms will have high PE ratios caused by high growth recruiting more investors even if the underlying company has produced low earnings so far.
XRAY currently has a 12-month-forward-PE-to-Growth (PEG) ratio of 0.8. The market is currently fairly valuing XRAY in relation to its projected growth due to the PEG ratio being around the fair market value of 1. XRAY's PEG comes from its forward price to earnings ratio being divided by its growth rate. Because PEG ratios include more fundamentals of a company's overall health with additional focus on the future, they are one of the most used valuation metrics by analysts.
XRAY's valuation metrics are adequate at its current price due to a fairly valued PEG ratio despite strong growth. XRAY's PE and PEG are around the market average resulting in a average valuation score.
Click Here to get the full Report on DENTSPLY SIRONA Inc (XRAY) stock.